United States:
Sample Shaming : FDA's Open Letter On Access To Samples
06 November 2018
Shearman & Sterling LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Senior associate Timothy Slattery (Washington, D.C.-Antitrust)
has authored the article "Sample Shaming: FDA's Open
Letter on Access to Samples Under REMS Programs Publically Calls
Out Branded Drug Manufacturers to Aid Generic Entry" in
Antitrust Advisors, a publication of the American Health
Lawyers Association Antitrust Practice Group. The article was
published in September 2018.
Read Sample Shaming: FDA's Open Letter on
Access to Samples Under REMS Programs Publically Calls Out Branded
Drug Manufacturers to Aid Generic Entry
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Antitrust/Competition Law from United States
EC Revises Notice On Market Definition
Ropes & Gray LLP
27 years after the first edition, the European Commission ("EC") adopted on 8 February 2024 a revised Market Definition Notice (the "Revised Notice")...